Publications
33
Citations
282
Est. group size
—
Recurring co-author estimate
Active years
18
Publishing since 2009
Terri Guinipero's work focuses on pediatric blood cancers, particularly acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and mixed phenotype acute leukemia (a leukemia type showing features of more than one blood cell lineage) in children. Research includes clinical trials of targeted drug therapies (such as nilotinib and antibody-drug conjugates), diagnostic classification standards, and tracking of residual disease and treatment outcomes in young leukemia patients.
Publication output has been fairly steady over the past decade, averaging just under 3 papers per year in the last 5 years, with a gap in 2024 followed by renewed output in 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML).
Journal of Clinical Oncology · 2025
- The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
Blood Advances · 2023
- Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML
Blood · 2023
- Real-World Performance of 2022 Revised World Health Organization (WHO) Criteria for Mixed Phenotype Acute Leukemia (MPAL) B/Myeloid Defined Only By Isolated MPO Expression (isoMPO)
Blood · 2023
- Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
Blood · 2022
- B‐cell acute lymphoblastic leukemia with <scp>iAMP21</scp> in a patient with Down syndrome due to a constitutional isodicentric chromosome 21
American Journal of Medical Genetics Part A · 2022
- A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety
Blood Advances · 2021
- Standardization in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL): Semiquantitative, Universally Applicable Flow Cytometric Criteria for Immunophenotypic Lineage Assignment and Isolated MPO
Blood · 2021
- Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study
Leukemia · 2020
- Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia
Blood · 2019
- Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients
Pediatric Blood & Cancer · 2019
- PF412 A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE CHRONIC MYELOID LEUKEMIA (CML): SAFETY UPDATE AFTER 36 CYCLES OF TREATMENT
HemaSphere · 2019
- Minimal Residual Disease Risk-Stratification in Pediatric Mixed Phenotype Acute Leukemia: Results of a Multi-Center Cohort Study
Blood · 2018
- Clinical Outcomes in Pediatric Mixed Phenotype Acute Leukemia (MPAL) Differ Depending on Disease Classification Criteria; A Multi-Center Cohort Study
Blood · 2018
- Blood×9
- Pediatric Blood & Cancer×4
- Blood Advances×2
- Journal of Clinical Oncology×2
- Journal of Pediatric Hematology/Oncology×1
- Yosra Ben Youssef
Medicine · The Ohio State University
- C. D. Bloomfield
Medicine · The Ohio State University
- Sai Prasad Desikan
Medicine · The Ohio State University
- Jessica Kohlschmidt
Medicine · The Ohio State University
- Tracelyn Freeman
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile